Home
Drugs
Tacrolimus
Clinical Trials

Clinical Trials Related to Tacrolimus

Related studies linked through entity extraction aliases.

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Status: NOT_YET_RECRUITING
Phase: PHASE2

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

Status: RECRUITING
Phase: PHASE2

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Status: NOT_YET_RECRUITING
Phase: PHASE1

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks

Status: NOT_YET_RECRUITING
Phase: NA

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Status: RECRUITING
Phase: PHASE2

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Status: RECRUITING
Phase: PHASE2/PHASE3

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Status: RECRUITING
Phase: PHASE2

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Status: NOT_YET_RECRUITING
Phase: PHASE4

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Status: NOT_YET_RECRUITING
Phase: PHASE2

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Status: NOT_YET_RECRUITING
Phase: PHASE1

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Status: RECRUITING
Phase: PHASE2

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Status: RECRUITING
Phase: PHASE2

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Status: RECRUITING
Phase: PHASE2

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Status: RECRUITING
Phase: PHASE2/PHASE3

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Status: NOT_YET_RECRUITING
Phase: PHASE2

Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome

Status: COMPLETED
Phase: NA

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Status: RECRUITING
Phase: PHASE1

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Status: RECRUITING
Phase: PHASE3

Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT

Status: RECRUITING
Phase: NA